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Patient stratiﬁcation has been instrumental for the success of targeted therapies in breast
cancer. However, the molecular basis of metastatic breast cancer and its therapeutic
vulnerabilities remain poorly understood. Here we show that PML is a novel target in
aggressive breast cancer. The acquisition of aggressiveness and metastatic features in breast
tumours is accompanied by the elevated PML expression and enhanced sensitivity to its
inhibition. Interestingly, we ﬁnd that STAT3 is responsible, at least in part, for the
transcriptional upregulation of PML in breast cancer. Moreover, PML targeting hampers
breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies
on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter
region. Altogether, we identify a novel pathway sustaining breast cancer aggressiveness that
can be therapeutically exploited in combination with PML-based stratiﬁcation.
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P
atient stratiﬁcation for cancer therapy is an excellent
illustration of precision medicine, and biomarker-based
treatment selection has tremendously aided in the success
of current cancer therapies1. In this sense, the current ability to
molecularly deﬁne and differentiate breast cancer (BCa) into
molecular subtypes2,3 has allowed the identiﬁcation of patients at
risk of relapse4 and has led to biomarker signatures used to spare
low-risk patients from aggressive chemotherapy5.
Tumours are heterogeneous entities and most cancers retain a
differential fraction of cells with increased self-renewal capability
(cancer stem or initiating cells)6. Cancer-initiating cells (CICs)
exhibit a unique spectrum of biological, biochemical and
molecular features that have granted them an important role in
disease recurrence and metastatic dissemination in BCa7,8.
Despite the accepted relevance of CICs in cancer progression,
the molecular cues governing their activity and function remain
largely unknown. The sex determining region Y Box 9 (SOX9)
is a recently described regulator of cell differentiation and
self-renewal9–11 and is found upregulated in BCa12–14.
The promyelocytic leukaemia (PML) protein negatively
regulates survival and proliferation pathways in cancer, functions
that have established it as a classical pro-apoptotic and
growth inhibitory tumour suppressor15,16. PML is the essential
component of multi-protein sub-nuclear structures commonly
referred to as the PML nuclear bodies. PML multimerizes to
function as a scaffold critical for the composition and assembly
of the entire complex, a process that is regulated by Small
Ubiquitin-like Modiﬁer (SUMO)-mediated modiﬁcations and
interactions15,16. Despite the general perception of being PML a
bona ﬁde tumour suppressor in cancer, a series of recent studies
have demonstrated that PML exhibits activities in cancer that go
far and beyond tumour suppression17. The work in chronic
myeloid leukaemia has evidenced that PML expression can be
promoted in certain cancers, providing a selective advantage to
tumour cells18,19. Moreover, PML is found upregulated in a
subset of BCa20. However, to which extent PML targeting could
be a valuable therapeutic approach in solid cancers remains
obscure.
In this study, we reveal the therapeutic and stratiﬁcation
potential of PML in BCa and the molecular cues, underlying the
therapeutic response unleashed by PML inhibition.
Results
PML silencing hampers BCa-initiating cell capacity. The
elevated expression of PML in a subset of BCa17,20 strongly
suggests that it could represent an attractive target for therapy. To
ascertain the molecular and biological processes controlled by
PML in BCa, we carried out short hairpin RNA (shRNA)
lentiviral delivery-mediated PML silencing in different cellular
systems. Four constitutively expressed shRNAs exhibited activity
against PML (Fig. 1a; Supplementary Fig. 1a–d). PML knockdown
elicited a potent reduction in the number of ALDH1-positive cells
and in oncosphere formation (OS, readout of self-renewal
potential7,21), in up to three PML-high-expressing basal-like
BCa (BT549 and MDA-MB-231) or immortalized (HBL100) cell
lines tested (Fig. 1b–d; Supplementary Fig. 1e–g). This phenotype
was recapitulated with a doxycycline-inducible lentiviral shRNA
system targeting PML (sh4; Fig. 1e,f; Supplementary Fig. 1h).
Self-renewal capacity is a core feature of CICs7. On the basis of
this notion, we hypothesized that PML could regulate tumour
initiation in BCa. We performed tumour formation assays
in immunocompromised mice, using MDA-MB-231 cells
(PML-high-expressing triple-negative breast cancer (TNBC))
transduced with non-targeting (shRNA Scramble: shC) or
PML-targeting shRNAs. PML silencing exhibited a profound
defect in tumour formation capacity, resulting in a decrease in the
frequency of tumour-initiating cells from 1/218 (shC) to 1/825
(sh5) and completely abolished (1/inﬁnite) in sh4 (Fig. 1g;
Supplementary Fig. 1i).
To extrapolate these observations to the complexity of human
BCa, we characterized a series of patient-derived xenografts
(PDXs; Table 1; Supplementary Fig. 1j). The distribution of
PML expression in the different subtypes of engrafted tumours
was reminiscent of patient data, with a higher proportion
of PML-high-expressing tumours in basal-like/triple-negative
subtype20. Taking advantage of the establishment of a
PML-high-expressing PDX-derived cell line (PDX44), we
sought to corroborate the results obtained in the PML-high-
expressing cell lines. As with MDA-MB-231 cells, PML silencing
was effective in the PDX44-derived cell line (Fig. 1h) and resulted
in a signiﬁcant decrease in OS formation (Fig. 1i). In vivo, PML
silencing decreased tumour-forming capacity of PDX44 cells
(tumour-initiating cell frequency was estimated of 1/39.6 in shC,
1/100 in sh5 and 1/185 in sh4; Fig. 1j; Supplementary Fig. 1k).
These data demonstrate that PML expression is required for
BCa-initiating cell function in TNBC cells.
PML sustains metastatic potential in BCa. CIC activity is
associated with tumour initiation and recurrence7,22. We have
previously shown that PML expression is associated to early
recurrence20, which we validated in an independent data set23
(Supplementary Fig. 2a). The development of metastatic lesions is
based on the acquisition of novel features by cancer cells24. On
the basis of our data, we surmised that the activity of PML on
CICs could impact on the survival and growth in distant organs.
To test this hypothesis, we measured metastasis-free survival
(MFS) in two well-annotated large messenger RNA (mRNA) data
sets3,25,26. First, we evaluated the impact of high PML expression
in MFS in the MSK/EMC (Memorial Sloan Kettering Cancer
Center-Erasmus Medical Center) data set25,26. As predicted,
PML expression above the mean was associated with reduced
MFS (Fig. 2a). Second, we validated this observation in the
METABRIC data set, focusing on early metastasis (up to
5 years)3. On the one hand, we conﬁrmed the MSK/EMC data
(Fig. 2b; hazard ratio (HR)¼ 1.31, log-rank test P¼ 0.006).
On the other hand, a Cox continuous model demonstrated an
association of PML expression with the increased risk of
metastasis (HR¼ 2.305, P¼ 0.002). Of note, we tested the
expression of PML in patients with complete pathological
response or residual disease after therapy27, but could not ﬁnd
a signiﬁcant association of these parameters in two data sets
(Supplementary Fig. 2b).
The molecular alterations associated to metastatic capacity can
be studied using BCa cell lines, in which metastatic cell sub-clones
have been selected through the sequential enrichment in
immunocompromised mice28. If PML is a causal event in the
acquisition of metastatic capacity, then changes in its expression
should be observed in this cellular system. As predicted,
PML mRNA and protein expression were elevated in three
distinct metastatic sub-clones compared with their parental
counterparts25,26 (Fig. 2c; Supplementary Fig. 2c).
Metastasis surrogate assays provide valuable information about
the capacity of cancer cells to home and colonize secondary
organs29. TNBC cells exhibit metastatic tropism to the lung30,
and the molecular requirements of this process have begun to be
clariﬁed through the generation of highly metastatic sub-clones31.
Our patient analysis suggests that PML expression is favoured in
primary tumours, with higher capacity to disseminate. Moreover,
cell sub-clone analysis further reveals that PML expression is
selected for in the process of metastatic selection. With this data
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in mind, we asked to which extent PML would be responsible for
the enhanced metastatic capacity. To address this question,
we silenced PML in a highly metastatic sub-clone derived from
MDA-MB-231 and injected these cells in the tail vein of nude
mice. We chose tail vein injection due to the fact that other
metastasis models based on the orthotopic implantation of cells in
the mammary fat pad25 are inﬂuenced by primary tumour
formation, which we reported to be altered by PML (Fig. 1). The
reduction of PML was conﬁrmed in the injected cells (Fig. 2d).
Strikingly, PML silencing led to a signiﬁcant reduction in lung
metastatic foci formation (Fig. 2e). When evaluating the
immunoreactivity of PML in the metastatic lesions (Fig. 2e–g),
we observed a direct association between PML silencing at the
time of injection (Fig. 2d) and the immunoreactivity of PML in
metastatic foci (Fig. 2g). We evaluated whether the lack of
PML could be limiting metastatic growth capacity by eliciting
an apoptotic response, rather than CIC capacity. However,
no differential apoptosis was detected by the means of cleaved
caspase-3 staining (Supplementary Fig. 2d–e).
These data demonstrate that the genetic targeting of PML
results in a tumour-suppressive response, characterized by
decreased BCa-initiating cell function and consequently, reduced
tumour initiation and metastasis.
STAT3 participates in the regulation of PML expression. Our
data demonstrate that PML is transcriptionally regulated in BCa.
PML gene expression is regulated upon various external stimuli,
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Figure 1 | Genetic targeting of PML hampers breast cancer initiation potential. (a) PML levels (representative western blot out of four independent
experiments) upon PML silencing with two shRNAs (sh) in MDA-MB-231 cells. (b) Percentage of ALDH1þ cells upon PML silencing with two shRNAs in
MDA-MB-231 cells (n¼4). (c) Representative ﬂow cytometry analysis out of three independent experiments of the ALDH1þ population in shC or
shPML-transduced MDA-MB-231 cells (FITC: ﬂuorescein-isothiocyanate, SSC-A: side-scatter). (d) Effect of PML silencing on primary (OSI) and secondary
(OSII) OS formation in MDA-MB-231 cells (n¼ 5 for OSII in shPML cells and n¼ 6 for shC and OSI in shPML cells). (e,f) PML levels (representative
western blot out of three independent experiments) (e) and OS formation (n¼ 3) (f) upon PML inducible silencing (shPML#4) with the indicated doses of
doxycycline in MDA-MB-231 cells. (g) Limiting dilution experiment after xenotransplantation. Nude mice were inoculated with 500,000 or 50,000
MDA-MB-231 cells (n¼ 12 injections per experimental condition). Tumour-initiating cell number was calculated using the ELDA platform. A log-fraction
plot of the limiting dilution model ﬁtted to the data is presented. The slope of the line is the log-active cell fraction (solid lines: mean; dotted lines: 95%
conﬁdence interval; circles: values obtained in each cell dilution). (h) PML levels (representative western blot out of four independent experiments) upon
PML silencing in the PDX44-derived cell line. (i) OSI formation upon PML silencing in PDX44 cells (n¼ 3). (j) Limiting dilution experiment after
xenotransplantation. Nude mice were inoculated either with 100,000 or 10,000 PDX44 cells (n¼ 20 injections per experimental condition).
Tumour-initiating cell number was calculated using the ELDA platform as in g. Error bars represent s.e.m., P value (*Po0.05; **Po0.01; ***Po0.001
compared with shC or as indicated). Statistics test: one-tail unpaired t-test (b,d,i), analysis of variance (f) and w2-test (g,j). dox, doxycycline;
OS, oncospheres; shC, Scramble shRNA; sh2, sh4 and sh5, shRNA against PML.
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including type I and II interferons and interleukin 6, which are
mediated by interferon regulatory factors and signal transducers
and activators of transcription (STATs), respectively32–35.
Speciﬁcally, it has been reported that activated STAT3 but not
STAT1 correlates with PML mRNA and protein levels in
ﬁbroblasts, HeLa and U2OS cell lines34. Since, STAT3 is
activated in oestrogen receptor (ER)-negative BCa36, we
hypothesized that this transcription factor may be responsible
for the transcriptional activation of PML in this tumour type. We
silenced STAT3 with two different short hairpins (sh41 and sh43),
and showed that this approach led to the decrease in PML protein
and gene expression in the different cell lines tested (Fig. 3a;
Supplementary Fig. 3a–b). Moreover, pharmacological inhibition
of the Janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway at two different levels
(SI3-201, an inhibitor of STAT3 phosphorylation and
activation; TG1013148, a potent and highly selective ATP-
competitive inhibitor of JAK2) decreased PML levels (Fig. 3b,c).
In coherence with the activity of PML, genetic and
pharmacological inhibition of STAT3 in MDA-MB-231 cells
reduced the primary OS formation capacity (Fig. 3d–f).
Importantly, PML gene expression levels in a cohort of 448
patients (MSK/EMC) correlated with the activity of STAT3, as
conﬁrmed with two different STAT3 signatures (Fig. 3g; ref. 37;
http://software.broadinstitute.org/gsea/msigdb/cards/V$STAT3_01).
In addition, immunohistochemical analysis conﬁrmed an
association between the PML immunoreactivity and phospho-
rylated STAT3 levels in the Marseille cohort (Fig. 3h). Our results
provide strong support for the role of STAT3 as an upstream
regulator of PML in BCa.
Elevated PML expression predicts response to arsenic trioxide.
PML can be pharmacologically inhibited with arsenic trioxide
(Trisenox, ATO), which induces SUMO-dependent ubiquityla-
tion and proteasome-mediated degradation of the protein38,39.
Similar to our results obtained by knocking down PML via
shRNA, low doses of ATO decreased PML levels and exerted a
negative effect on the OS formation capacity both in MDA-MB-
231 and PDX44 cells (Fig. 4a,b). Moreover, ATO reduced the
tumour formation capacity in a xenograft model derived from
MDA-MB-231 cells in full coherence with the genetic approach
(tumour-initiating cell frequency was estimated of 1/279 in
vehicle and 1/703 in ATO; Fig. 4c; Supplementary Fig. 4a).
We hypothesized that cells with elevated PML would be
‘addicted’40 to the expression of the protein and hence be more
sensitive to the action of PML inhibitors. To prove this notion, we
studied additional cell lines with high (BT549, HBL100) or low
(MCF7, T47D) PML expression. With this approach, we could
demonstrate that the effect of PML silencing on the OS formation
was exquisitely restricted to PML-high-expressing cells (Fig. 4d).
This effect was recapitulated with ATO (Fig. 4e), where PML-low
cells remained refractory to the drug in terms of the OS formation
capacity.
Our results open a new avenue for the treatment of tumours
that exhibit elevation in PML expression. PML elevation is
predominant in ER-negative tumours (Supplementary Fig. 4b),
which also present worse prognosis than ER-positive BCa2,41.
Whereas luminal subtypes present better overall prognosis, there
is a subset of patients within this subtype that exhibits aggressive
disease42. We hypothesized that within this PML-low-expressing
subtypes, the worse prognosis subgroup would exhibit increased
PML levels. Indeed, MFS analysis within each intrinsic subtype
conﬁrmed that ER-positive BCa (luminal A and luminal B)
contained a subset of patients with higher PML and worse
prognosis (Supplementary Fig. 4c–g).
Our results in ER-positive tumours indicate that the PML
expression is enriched in patients harbouring tumours of poor
prognosis2,3. These results are coherent with our data in
metastatic clone selection (Fig. 2c), suggesting that the
acquisition of aggressive features is accompanied by the
elevation of PML expression and ‘addiction’ to the protein. We
therefore sought to study whether metastatic ER-positive cell
sub-clones, which present elevated PML expression, would
exhibit sensitivity to PML inhibition, in contrast to the parental
cells. Indeed, ATO reduced the OS formation selectively in
PML-high-expressing metastatic cells derived from MCF7,
whereas the parental cells remained refractory to the drug
(Fig. 4f,g). Our results strongly suggest that PML elevation in BCa
is associated to a dependence on its expression and hence
enforces the need for patient stratiﬁcation based on PML levels
before the establishment of PML-directed therapies.
PML regulates BCa-initiating cell function through SOX9.
To ascertain the molecular mechanism by which PML regulates
BCa-initiating cell function, we ﬁrst evaluated the expression
levels of this gene in a sorted population of ALDH1-positive
versus -negative MDA-MB-231 cells (Fig. 5a,b), and in adherent
cultures versus OS (CIC-enriched cultures) (Fig. 5c). Strikingly,
PML expression increased in both experimental approaches
(Fig. 5b,c), together with the levels of well-established stem cell
regulators (Fig. 5c). On this basis, we hypothesized that PML
might control the expression of stem cell factors, as a mean to
regulate BCa-initiating cell function. SOX9 is a recently described
regulator of cell differentiation and self-renewal9,10,11 and is
upregulated in BCa12–14. Constitutive (Fig. 5d; Supplementary
Fig. 5a–b) and inducible (Fig. 5e) PML silencing exerted an
inhibitory effect on SOX9 expression that correlated with the OS
formation capacity (Fig. 5f). PML pharmacological inhibition also
induced a decrease on SOX9 expression (Fig. 5g; Supplementary
Fig. 5c–d). This regulatory activity was corroborated in the
PDX44 cell line (Fig. 5h,i; Supplementary Fig. 5e), and in a
Table 1 | PDX characterization based on BCa subtype
(intrinsic subtype is presented in brackets).
PDX Subtype PML
31 TNBC (HER2 enriched) 
102 ERþ (basal like) 
131 ERþ (luminal B) 
156 ERþ (basal like) 
197 TNBC (basal like) 
4 ERþ (luminal B) þ
6 ERþ (luminal A) þ
10 HER2þ (HER2 enriched) þ
39 ERþ (luminal B) þ
60 ERþ (basal like) þ
98 ERþ (basal like) þ
136 TNBC (basal like) þ
137 TNBC (basal like) þ
161 ERþ (luminal B) þ
93 TNBC (NA) þ þ
179 TNBC (NA) þ þ
44 TNBC (basal like) þ þ þ
88 TNBC (basal like) þ þ þ
89 TNBC (NA) þ þ þ
94 TNBC (basal like) þ þ þ
124 TNBC (basal like) þ þ þ
127 TNBC (basal like) þ þ þ
167 TNBC (basal like) þ þ þ
ER, oestrogen receptor; NA, not applicable; TNBC, triple-negative breast cancer.
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correlative manner in the PDX data set (Fig. 5j), as well as in the
aforementioned Marseille data set (Fig. 5k).
We next ascertained the molecular cues regulating SOX9
expression downstream PML. Since the regulation was observed
at the mRNA level, we interrogated SOX9 promoter in silico and
in public datasets. The ENCODE project has provided a vast
amount of information about regulators and binding sites43.
SOX9 promoter exhibited a 2 kb region of acetylated H3K27
(H3K27Ac), which would indicate the proximal regulatory
region. To our surprise, we found PML among the 10 proteins
with highest conﬁdence DNA-binding score in SOX9 promoter
region (Fig. 5l; cluster score¼ 527 (refs 44–46)). There is limited
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evidence of the capacity of PML to regulate gene expression
in concordance with transcription factors through association
with DNA47–49. We performed chromatin immunoprecipitation
(ChIP) analysis of ectopically expressed and endogenous PML,
as well as SOX9 expression analysis in these conditions.
We conﬁrmed that PML is in close proximity to SOX9
promoter region and that its ectopic expression upregulates
SOX9 transcript and protein levels (Fig. 5m; Supplementary
Fig. 5f–j). It is worth noting that PML does not present a
canonical DNA-binding domain, and it is therefore plausible that
it lies in close proximity to SOX9 promoter through the
interaction with intermediary DNA-binding proteins.
The regulation of SOX9 led us to hypothesize that this
transcription factor mediated the effects of PML on the regulation
of CIC function. On the one hand, we ascertained whether SOX9
silencing would recapitulate the effects of PML inhibition. We set
up two shRNAs targeting SOX9 (Fig. 6a) that exhibited a potent
effect on primary (Fig. 6b) and secondary (Supplementary Fig. 6a)
OS formation. Moreover, SOX9 silencing in MDA-MB-231 cells
reduced the tumour formation capacity in vivo (tumour-initiating
cell frequency was estimated of 1/71.7 in shC, completely abolished
(1/inﬁnite) in sh9.1 and 1/4145.5 in sh9.2; Fig. 6c; Supplementary
Fig. 6b–c), in agreement with other reports12.
On the other hand, we evaluated the capacity of ectopically
expressed SOX9 to bypass the effects of PML silencing on CIC
function. Ectopic SOX9-expressing BCa cells were refractory to
PML genetic inhibition in terms of the OS formation (Fig. 6d,e)
and tumour formation (tumour-initiating cell frequency was
estimated of 1/139.8 in shC/Mock, 1/57.5 in shC/SOX9, 1/1506 in
sh4/Mock and 1/270.8 in sh4/SOX9; Fig. 6f; Supplementary
Fig. 6d). Importantly, the in vitro observation was recapitulated in
ATO-treated cells (Fig. 6g).
These data reveal a novel molecular mechanism by which
PML controls the expression of the stem cell factor SOX9 to
regulate BCa-initiating cell function (Fig. 6h). It is worth
noting that we found PML at the promoter region of other stem
cell genes, such as LGR5 (Supplementary Fig. 6e–g), indicating
that the capacity of this protein to regulate CIC function
could involve a larger and more complex transcriptional
program.
Discussion
Finding successful targeted treatment strategies for women at risk
of metastatic BCa is of outstanding clinical interest. Our data
unveil the therapeutic potential of targeting PML in combination
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with a stratiﬁcation companion that identiﬁes patients harbouring
PML-high-expressing BCa.
We demonstrate that PML targeting impacts on BCa-initiating
cell function, and hence on cancer initiation and dissemination.
In addition, we observed that PML expression is increased in
BCa-initiating cells, highly metastatic sub-clones and in BCa
patients at risk of metastasis. These data suggest that, in a subset
of BCas, PML sustains the function of BCa-initiating cells and in
turn supports the metastatic dissemination capacity6.
We show that PML-directed therapies are efﬁcient in BCa cells
with elevated expression of the protein. Such phenomenon has
been deﬁned as ‘addiction’40,50,51, and it represents an exciting
avenue in the establishment of novel therapeutic initiatives.
Importantly, targeted therapies have been particularly successful
when combined with a predictive biomarker. The availability of a
clinically validated protocol to detect PML immunoreactivity52
offers a unique opportunity to deﬁne the patients that would
beneﬁt from therapies based on PML inhibition. In addition, our
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proof-of-concept demonstration of the therapeutic efﬁcacy of
PML pharmacological inhibition with ATO indicates that
(1) repositioning of ATO (that is currently used in the
treatment of acute PML) for BCa therapy is a viable approach,
(2) there is strong support for the development of novel and more
effective PML inhibitors and (3) the identiﬁcation of combined
therapies with PML inhibitors in BCa is a novel and exciting area
of investigation.
Mechanistically, our data demonstrate that PML is in close
proximity to the promoter region of SOX9, and positively
regulates the expression of the gene. SOX9 has been recently
established as a central regulator of normal and cancer stem
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cells9–13,53–61. This activity is executed in part through the
functional interplay with epithelial-to-mesenchymal transition
regulators such as SLUG12,53,56. In BCa, SOX9 is found
overexpressed in the TNBC subtype, and regulates the
WNT/beta-catenin pathway14. In addition, this transcription
factor is a main driver of the transcriptional signature of this
subtype of BCa62. All these features make SOX9 an ideal target
for BCa therapy. However, development of small molecules
targeting transcription factors has been an outstanding challenge
with limited success63. Our data demonstrating that PML sustains
SOX9 expression in aggressive BCa opens the possibility to bypass
this limitation and inhibit the function of the transcription factor
through upstream PML targeting.
In summary, our data provide proof-of-concept demonstration
of the fact that PML-inhibiting compounds could exhibit strong
potential for BCa therapy upon PML-based stratiﬁcation.
Methods
Cell culture. MDA-MB-231, BT594, HBL100, MCF7 and T47D cell lines were
obtained from the American Type Culture Collection (Manassas, VA, USA)
or from Leibniz-Institut—Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DMSZ, Germany), who provided an authentication
certiﬁcate. None of the cell lines used in this study was found in the database of
commonly misidentiﬁed cell lines maintained by ICLAC and NCBI biosample.
PDX44-derived cell line was generated by Dr Ibrahim and Dr Serra starting from
xenograft tumours. Cell lines were routinely monitored for mycoplasma
contamination and quarantined, while treated if positive. All cell lines were
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circles: values obtained in each cell dilution). (d,e) Effect of ectopic SOX9 expression on the consequences of PML silencing. Representative western blot
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maintained in DMEM media supplemented with 10% (v/v) foetal bovine serum
and 1% (v/v) penicillin–streptomycin. OS formation assays were carried out as
previously described64. In brief, single-cell suspensions were plated in six-well
tissue culture plates covered with poly-2-hydroxyethyl-methacrylate (Sigma,
St Louis, MO) to prevent cell attachment, at a density of 3,000 cells per ml in
serum-free DMEM supplemented with 1% penicillin/streptomycin, 1% B27
(Invitrogen, Carlsbad, CA, USA), 10 ngml 1 epidermal growth factor (EGF)
(Sigma, St. Louis, MO) and 2 ngml 1 ﬁbroblast Growth Factor, basic (FGFb)
(Invitrogen, Carlsbad, CA, USA). After 6 days in culture, OS were counted using a
light microscope. For secondary OS formation, following the same protocol,
100,000 cells were plated in 100mm dishes and collected by gentle centrifugation
(200g) and dissociated enzymatically (5min in 1:1 TrypLE solution at 37 C, Life
Technologies, cat: 12604013) and single cells were re-plated at a density of 3,000
cells per ml in six-well tissue culture plates for 6 days.
Generation of stable cell lines. 293FT cells were used for lentiviral production.
Lentiviral vectors expressing shRNAs against human PML, STAT3 and SOX9 from
the Mission shRNA Library were purchased from Sigma-Aldrich or Addgene. Cells
were transfected with lentiviral vectors following standard procedures, and viral
supernatant was used to infect cells. Selection was done using puromycin
(2mgml 1) for 48 h. As a control, a lentivirus with scrambled shRNA (shC) was
used. Short hairpins sequence: sh1PML (TRCN0000003865): CCGGCAATACAA
CGACAGCCCAGAACTCGAGTTCTGGGCTGTCGTTGTATTGTTTTT,
sh2PML (TRCN0000003865): CCGGCAATACAACGACAGCCCAGAACTC
GAGTTCTGGGCTGTCGTTGTATTGTTTTT; sh4PML (TRCN 0000003867):
CCGGGCCAGTGTACGCCTTCTCCATCTCGAGATGGAGAAGGCGTACACT
GGCTTTTT; sh5PML (TRCN 0000003867): CCGGGTGTACCGGCAGATTGT
GGATCTCGAGATCCACAATCTGCCGGTACACTTTTT; shC: CCGGCAACAA
GATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG. sh41STAT3
(TRCN0000020841): CCGGGCTGAAATCATCATGGGCTATCTCGAGATAGC
CCATGATGATTTCAGCTTTTT; sh43STAT3 (TRCN0000020843): CCGGGCAA
AGAATCACATGCCACTTCTCGAGAAGTGGCATGTGATTCTTTGCTTTTT.
sh1SOX9 (Addgene, GenBank ID: RHS3979-9587792; GCATCCTTCAATTTCTG
TATA); sh2SOX9 (TRCN0000342824): CCGGCTCCACCTTCACCTACATGAAC
TCGAGTTCATGTAGGTGAAGGTGGAGTTTTTG. Sub-cloning of shC and
sh4PML into pLKO-Tet-On vector was done introducing AgeI and EcoRI in the
50-end of top and bottom shRNA oligos, respectively (following the strategy
provided by Dr Dmitri Wiederschain65, Addgene plasmid: 21915). HA-PMLIV was
sub-cloned into a TRIPZ vector using Age1–Mlu1 sites.
Immunoassays. Western blot analysis was carried out as previously described20.
Uncropped scans are provided as part of the Supplementary Information
(Supplementary Fig. 7). In brief, cells were seeded on six-well plates and 4 days
(unless otherwise speciﬁed) after seeding cell lysates were prepared with RIPA
buffer (50mM TrisHCl pH 7.5, 150mM NaCl, 1mM EDTA, 0.1% SDS, 1%
Nonidet P40, 1% sodium deoxycholate, 1mM sodium ﬂuoride, 1mM sodium
orthovanadate, 1mM beta-glycerophosphate and protease inhibitor cocktail;
Roche). The following antibodies were used for western blotting: rabbit polyclonal
anti-PML, 1:1,000 dilution (cat: A301-167A; Bethyl laboratories), rabbit polyclonal
anti-phospho-STAT3 (Tyr705) 1:1,000 dilution and total STAT3 1:1,000 dilution
(cat: 9145, 9132 respectively; Cell Signaling), rabbit polyclonal anti-SOX9 1:2,000
dilution (cat: AB5535; CHEMICON International), HA-Tag polyclonal antibody
1:2,000 dilution (cat: C29F4, Cell Signaling Technology, Inc) and mouse
monoclonal anti-beta-ACTIN 1:2,000 dilution (clone: AC-74, catalogue: A5316,
Sigma-Aldrich). After standard SDS–polyacrylamide gel electrophoresis and
western blotting techniques, proteins were visualized using the enhanced
chemiluminescence (ECL) system.
For immunoﬂuorescence, cells were seeded on glass cover slips in 24-well plates
and 4 days after seeding, cells were ﬁxed with 4% paraformaldehyde (15min), PBS
(three times wash), 1% Triton X-100 (5min), PBS (three times wash), 10% goat
serum (1 h) and anti-PML antibody 1:100 ditution (catalogue A301-167A; Bethyl
laboratories) was added overnight (4C) in goat serum. Cover slips were washed
with PBS three times and incubated with secondary antibody (anti-rabbit Alexa488;
Invitrogen-Molecular Probes) for 1 h (room temperature). Cover slips were washed
with PBS three times, and 4,6-diamidino-2-phenylindole added to stain nuclei
(10min), followed by mounting with Mowiol. Immunoﬂuorescence images were
obtained with an AxioImager D1 microscope.
For immunohistochemistry, tissues were ﬁxed in 10% neutral-buffered formalin
and embedded in parafﬁn according to standard procedures. Three to four
mm-thick sections were stained for PML (clone PG-M3 Santa Cruz Biotechnology
Inc, sc-966, 1:200 dilution), and vimentin (1:1,000, NCL-L-VIM-V9, Novocastra).
Antigen retrieval was performed with citrate buffer (pH 6). Detection was
performed with the ABC Kit from Vector Laboratories and 3,30-diaminobenzidine
(DAB)-based development. Sections were counterstained with haematoxylin. The
PML general immunoreactivity scoring system (used in Fig. 1h) is described in ref.
20. For the Marseille data set, PML (1:200), SOX9 (1:400, Millipore) and phospho-
STAT3 (Tyr705) (1:100, Cell Signalling: M9C6) immunostaining was performed as
reported11,20. The percentage of PML-high (Ph) and -low (Pl) immunoreactive
tumour cells in the Marseille data set was quantiﬁed separately and the h-score was
calculated, attributing a relative value of 1 to Pl and 2 to Ph intensity nuclear
signal (h¼ (1 Pl)þ (2Ph)). For SOX9 automated quantiﬁcation and
construction of tissue microarrays (TMAs) in the Marseille data set was carried
out as reported23. In brief, cores were punched from the selected parafﬁn blocks,
and distributed in new blocks including two cores of 0.6 mm diameter for each
tumour. All the TMA blocks were stored at 4 C. TMA serial tissue sections were
prepared 24 h before immunohistochemistry processing and stored at 4 C. The
immunoperoxidase procedures were performed using an automated Ventana
Benchmark XT auto-stainer. This device allowed identical well-controlled
procedures for antigen retrieval and Ventana kits.
Quantitative real-time PCR. Cells were seeded as for western blot. Total RNA was
extracted from cells using NucleoSpin RNA isolation kit from Macherey-Nagel
(ref: 740955.240C). Complementary DNA was produced from 1 mg of RNA using
qScript cDNA SuperMixt (Quanta Bioscience, ref: 95048). Taqman probes were
obtained from Applied Biosystems. Ampliﬁcations were run in a Viia7 Real-Time
PCR System (Applied Biosystems) using the following probes: PML
(Hs00971694_m1, cat: 4331182) and SOX9 (Hs01001343_g1, cat: 4331182). For
STAT3, SOX2 and LGR5 ampliﬁcation, Universal Probe Library (Roche) primers
and probes were employed (STAT3, For: cccttggattgagagtcaaga, Rev: aagcggctatac
tgctggtc; probe: 14; SOX2, For: gggggaatggaccttgtatag, Rev: gcaaagctcctaccgtacca;
probe: 65; LGR5, For: accagactatgcctttggaaac, Rev: ttcccagggagtggattctat; probe: 78).
b-actin (Hs99999903_m1, cat: 4331182) and GAPDH (Hs02758991_g1, cat:
4331182) housekeeping assays from Applied Biosystems showed similar results
(all quantitative PCR with reverse transcription data presented were normalized
using GAPDH).
ALDH1 activity by FACS. To measure the ALDH1 activity present in the cells,
the ALDEFLUOR assay was carried out according to manufacturer’s (Stemcell
Technologies) guidelines. In brief, dissociated MDA-MB-231 cells were
resuspended in ALDEFLUOR assay buffer at a ﬁnal concentration of 1.106ml 1.
ALDH substrate, bodipyaminoacetaldehyde was added to the cells at a ﬁnal
concentration of 1.5mM. Immediately, half of the cells were transferred to an
Eppendorf tube containing a two fold molar excess of the ALDH inhibitor,
diethylaminobenzaldehyde. Both tubes were incubated for 45min at 37 C,
and after this incubation cells were centrifuged at 250g for 5min at 4 C and
resuspended in ice-cold ALDEFLUOR assay buffer. Cells were analysed using a
FACSAria1 (Becton Dickinson) ﬂow cytometer. DRAQ7 (BiostatuS) was added
prior analysis to each tube for dead cell exclusion. FACSAria1 was also used for
sorting cells. Data were analysed using the FACSDiva software.
Reagents. For in vitro experiments, SI3-201 (Sigma-Aldrich, SML0330) was
prepared at 10mgml 1 in dimethylsulfoxide and used at the indicated con-
centrations. TG101348 (Santa Cruz, sc-364740) was prepared 100mgml 1 in
dimethylsulfoxide and used at the indicated concentrations. ATO (Sigma-Aldrich)
was prepared at a concentration of 100mM in NaOH 1N and subsequently diluted
to 0.1mM in PBS for a 1,000 working solution. ATO was used at 150 nM either
3 or 6 days as indicated in ﬁgure legends. For in vivo experiments a dose of
5mg kg 1 per day was intraperitoneally administered.
Mice. Xenograft experiments were carried out following the ethical guidelines
established by the Biosafety and Welfare Committee at CIC bioGUNE and
Biodonostia Institute. The procedures employed were carried out following the
recommendations from AAALAC. Xenograft experiments were performed as
previously described66, injecting either 5.105 or 5.104 cells per condition (unless
otherwise speciﬁed), four injections per mouse. Metastasis experiment was
approved by the institutional animal care and use committee of IRB-Barcelona. For
tail vein injections, cells were resuspended in PBS and injected into tail vein of mice
using a 26G needle (1.2 105 cells per mouse), as previously described25. Cell lung
colonization capacity was scored 21 days post inoculation by human vimentin.
PML expression was scored as undetectable (PML 0) and detectable (PML 1þ ,
2þ and 3þ ). All mice (female Hsd:Athymic Nude-Foxn1 nu/nu) were inoculated
at 8–12 weeks of age.
ChIP. ChIP was performed using the SimpleChIP Enzymatic Chromatin IP Kit
(cat: 9003, Cell Signaling Technology, Inc). MDA-MB-231 cells were grown in
150mm dishes either with or without 50 ngml 1 doxycycline during 3 days.
Cells from three 150mm dishes (2.5 107 cells) were cross-linked with 35%
formaldehyde for 10min at room temperature. Glycine was added to dishes, and
cells incubated for 5min at room temperature. Cells were then washed twice with
ice-cold PBS, and scraped into PBSþ PMSF. Pelleted cells were lysed and nuclei
were collected following manufacturer’s instructions. Nuclear lysates were digested
with micrococcal nuclease for 20min at 37 C and then sonicated in 500 ml aliquots
on ice for three pulses of 15 s using a Branson sonicator. Cells were held on ice for
at least 1min between sonications. Lysates were clariﬁed at 11,000g for 10min at
4 C, and chromatin was stored at  80 C. HA-Tag polyclonal antibody (cat:
C29F4, Cell Signaling Technology), rabbit polyclonal anti-PML (cat: A301-167A;
Bethyl laboratories) and IgG antibody (cat: 2729, Cell Signaling Technology, Inc),
were incubated overnight (4 C) with rotation and protein G magnetic beads were
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incubated 2 h (4 C). Washes and elution of chromatin were performed following
manufacturer’s instructions. DNA quantiﬁcation was carried out using a Viia7
Real-Time PCR System (Applied Biosystems) with SybrGreen reagents and
primers that amplify the predicted PML binding region to SOX9 promoter
(chr17:70117013-70117409) as follows: left primer: ccggaaacttttctttgcag and right
primer: cggcgagcacttaggaag.
Patient data sets, bioinformatics and statistical analysis. All studies involving
human subjects were approved by the corresponding committees with informed
consent as stated in the original publications3,23,25. The use of MSK/EMC and
Marseille cohorts were previously described23,25. For MSK/EMC, MFS curves were
plotted using Kaplan–Meier estimates and compared using the Gehan–Breslow–
Wilcoxon test. Two groups were compared using mean PML expression values as
the cutoff between PML high and low. Kaplan–Meier survival and correlation
analysis in patient samples: publicly available and clinically annotated BCa cohorts
with gene expression proﬁles (GSE2603, GSE2034, GSE5327 and GSE12276) were
pooled as described above. To remove systematic biases, before merging the
expression measurements were converted to z scores for all genes. For intrinsic
subtype classiﬁcation, we carried out the following analysis: for luminal genes,
ESR1 and PGR1 presented a bimodal distribution. We used package mclust to ﬁt a
mixture of normal distributions with two components and obtain the posterior
probability that each patient belongs to the luminal low and luminal high
components. A patient was considered luminal low if the posterior probability of
belonging to this group was480%. The same criterion was used for luminal high.
When a patient was neither luminal high nor luminal low, it was considered
luminal intermediate. Proliferation status (Prol) and ERBB2 expression did not
present a bimodal distribution. Therefore, half of the patients with lowest mean
values were considered proliferation low. The rest were considered proliferation
high. After deﬁning high and low populations for each parameter, the subtypes
were constructed as follows: luminal A: Prol low, ESR1 intermediate or high,
luminal intermediate or high; luminal B: Prol high, ESR1 intermediate or high,
luminal intermediate or high; HER2 enriched: Prol high, ESR1 intermediate or low,
luminal intermediate or low; ERBB2 high; basal like: Prol high, ESR1 low, luminal
low; ERBB2 low, PGR1 low. Sixty-four patients could not be assigned to any
subtype according to PAM50’s classiﬁcation. A Cox proportional hazards model
was ﬁtted to compute HR. Likelihood ratio tests were performed to compute
P values. The HR was checked for constancy over time, fulﬁlling Cox model
assumptions.
For Curtis data set patients, RNA was extracted from 1,980 tumours as
described3. RNA hybridizations were performed using Illumina HT-12 v3 platform
and analysed using the bioconductor bead array package67. The BASH algorithm68
was applied to correct for spatial artefacts in the arrays. Bead-level data were
summarized and re-annotated as described in ref. 3. Log-intensity values for PML
expression were scaled to z scores. Probe selection was performed on the basis of
probe quality, 30-position, no other genomic matches and no single-nucleotide
polymorphisms in the region. On the basis of these criteria, PML probe
ILMN_1731299 was selected for analysis. Survival analysis was done using as
endpoints MFS at 5 years (distant metastasis as event). Two groups were compared
using mean PML expression values as the cutoff between PML high and low.
We used the log-rank test as implemented in the survival R package69.
For therapy response analysis, publicly available data sets (GSE22093 and
GSE23988) were downloaded from Gene Expression Omnibus (GEO), and
subjected to background correction, log2 transformation and quartile
normalization.
For correlation analysis with STAT3 signatures, gene sets were extracted (ref. 37,
and http://software.broadinstitute.org/gsea/msigdb/cards/V$STAT3_01) and
average signal value in the MSK/EMC data set was calculated. These values were
used to perform the correlation analysis with PML signal values (Pearson
correlation).
No statistics were applied to determine sample size. The experiments were not
randomized. The investigators were not blinded to allocation during experiments
and outcome assessment. Data analysed by parametric tests are represented by the
mean±s.e.m. of pooled experiments unless otherwise stated. n values represent the
number of independent experiments performed or the number of individual mice
or patient specimens. For each independent in vitro experiment, at least three
technical replicates were used and a minimum number of three experiments were
performed to ensure adequate statistical power. Analysis of variance test was used
for multi-component comparisons and Student’s t-test for two-component
comparisons. In the in vitro experiments, normal distribution was conﬁrmed or
assumed (for no5) and Student’s t-test was applied for two-component
comparisons. Two-tailed statistical analysis was applied for experimental design
without predicted result, and one tail for validation or hypothesis-driven
experiments. The conﬁdence level used for all the statistical analyses was of 0.95
(alpha value¼ 0.05). Tumour-initiating cell frequency was estimated using ELDA
software as previously described70.
Data availability. Data from public repositories analysed throughout this
manuscript (see the ‘Patient data sets, bioinformatics and statistical analysis’
section) is available as indicated in the referenced publications.
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